semaglutide + cagrilintide Cagrilintide vs Semaglutide: Which GLP-1

"Partners"

In this commentary, we summarize the potential effects of GLP-1RAs on CV parameters based on results from recent CV outcomes trials, and further discuss the clinical application of the agents in CV medicine

While companies moving into the GLP-1 space continue to target diabetes and obesity indications first, evidence is accruing for the drugs benefits in cardiac outcomes, and multiple players are looking to join Novo in using them to address these indications

Promotes healthy metabolic reactions*

They can even selectively express therapeutic molecules in response to disease-specific signals, thereby maintaining high treatment specificity [15]